utjecaj Theranekrona® na aktivnost glukoza-6-fosfat dehidrogenaze u neoštećenim jajnicima štakora i jajnicima štakora s ishemijsko- reperfuzijskom ozljedom

The effect of Theranekron® on rat ovaries was evaluated in healthy and ischemia-reperfusion injury models. The rats were divided into four groups: group 1: control, group 2: Theranekron® (single dose of 0.3 mg/kg intraperitoneally), group 3: torsion + detorsion, and group 4: torsion + detorsion + Theranekron® (single dose 0,3 mg/ kg, intraperitoneally). The ovaries were homogenized by sonication before the analysis and supernatant glucose-6- phosphate dehydrogenase activity, reduced nicotinamide adenine dinucleotide phosphate, reduced glutathione and total protein levels were evaluated spectrophotometrically. Ovary tissues were histologically examined. In group 2, glucose-6-phosphate dehydrogenase activity was significantly reduced (P<0.01) compared to the control group and an increased number of atretic follicles, and hyperaemic and haemorrhagic regions were seen histologically; in group 3, although glucose-6-phosphate dehydrogenase activity was not changed, intense hyperaemia and hemorrhage was observed in the veins of the medulla region and in the cortex. Group 4 showed a decrease in glucose-6-phosphate dehydrogenase activity compared to the control group (P<0.01). Histologically, when compared to group 3, group 4 showed fewer atretic follicles and decreased hyperaemia and hemorrhage in the ovaries, excluding the medulla region. There were no significant differences regarding reduced glutathione and reduced nicotinamide adenine dinucleotide phosphate levels between the groups. The Theranekron® dose applied had some negative effects, such as reduced glucose-6-phosphate dehydrogenase activity, an increased number of atretic follicles, and hyperemia in the corpus luteum and medulla region in intact rat ovaries. Although it reduced glucose-6-phosphate dehydrogenase activity, Theranekron® may have had slight remedial effects on rat ovaries with ischemia-reperfusion injury.Učinak Theranekrona® na jajnike štakora procijenjen je u zdravih jedinki i onih s ishemijsko-reperfuzijskom ozljedom. Štakori su podijeljeni u četiri skupine: prva je skupina bila kontrolna, druga je skupina dobivala Theranekron® (pojedinačna doza od 0,3 mg/kg intraperitonealno), treća je skupina imala torziju i detorziju, a četvrta je skupina imala torziju i detorziju i primala je Theranekron® (pojedinačna doza od 0,3 mg/kg intraperitonealno). Jajnici su homogenizirani sonikacijom prije analize te je spektrofotometrijom istražena aktivnost supernatant glukoza- 6-fosfat dehidrogenaze, smanjenje nikotinamid-adenin-dinukleotid-fosfata, smanjenje glutationa i razina ukupnih proteina. Histološki je analizirano tkivo jajnika. U drugoj skupini aktivnost glukoza-6-fosfat dehidrogenaze bila je znakovito smanjena (P < 0,01) u usporedbi s kontrolnom skupinom. Histološki, ustanovljen povećan broj atretskih folikula te hiperemičnih i hemoragičnih područja. U trećoj skupini, iako aktivnost glukoza-6-fosfat dehidrogenaze nije bila promijenjena, u venama medularne regije i korteksu uočena je jaka hiperemija i hemoragija. Četvrta skupina pokazala je smanjenu aktivnost glukoza-6-fosfat dehidrogenaze u usporedbi s kontrolnom skupinom (P < 0,01). U usporedbi s trećom skupinom, četvrta skupina pokazala je manje atretskih folikula i smanjenu hiperemiju i hemoragiju u jajnicima, osim medularne regije. Nije bilo znakovite razlike s obzirom na smanjene razine glutationa i nikotinamid- adenin-dinukleotid-fosfata među skupinama. Primijenjena doza Theranekrona® imala je neke negativne učinke poput smanjene aktivnosti glukoza-6-fosfat dehidrogenaze, povećanog broja atretskih folikula te hiperemije u žutom tijelu i medularnoj regiji intaktnih jajnika štakora. Iako je smanjio aktivnost glukoza-6-fosfat dehidrogenaze, Theranekron® bi mogao imati i neznatne terapijske učinke na jajnike štakora s ishemijsko-reperfuzijskom ozljedom